Invex Therapeutics Ltd. (AU:IXC) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Invex Therapeutics Ltd has announced the retirement of Dr. Megan Baldwin as a Non-executive director, effective 30 June 2024. Baldwin, who joined the biopharmaceutical company in February 2021, played a pivotal role in advancing their leading drug, Exenatide, from Phase II to Phase III clinical trials for treating neurological conditions related to increased intracranial pressure. The company expressed gratitude for her significant contributions and wished her well in future endeavors.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.